Glutamine Metabolism in Tumor Immunology

Glutamine serves as a central nutrient in both cancer cells and immune cells within the tumour microenvironment, supporting biosynthesis, energy production and redox balance. Tumour cells frequently exploit glutamine to fuel rapid proliferation and to modulate local immunosuppression, depleting this amino acid and starving effector lymphocytes. Conversely, immune populations such as dendritic cells and cytotoxic T lymphocytes depend on glutamine uptake and metabolic signalling to mount effective antitumour responses. Metabolic competition for glutamine thus represents a critical checkpoint in tumour–immune interplay, influencing antigen presentation, T-cell activation and checkpoint-mediated resistance. Recent advances have begun to unravel the transporters, enzymes and signalling pathways that determine glutamine partitioning between tumour and immune cells, offering new avenues to recalibrate metabolism in favour of durable immune surveillance.

Research from Nature Portfolio

Recent studies have shown that a specific transporter mediating glutamine uptake by type 1 conventional dendritic cells is pivotal for priming cytotoxic T cells and overcoming resistance to checkpoint blockade. Supplementation of glutamine within tumours augments dendritic cell function and potentiates CD8+ T-cell-mediated tumour clearance by altering nutrient competition. In parallel, targeting glutamine metabolism in pancreatic adenocarcinoma with a pro-drug antagonist induces a metabolic crisis in tumour cells, suppresses growth in vivo and reveals a compensatory increase in ERK signalling. Combining glutamine blockade with MEK pathway inhibition synergistically extends survival in preclinical models. Foundational work has also demonstrated that a nuclear regulator in CD8+ T cells limits mTOR complex 1 activity and glutaminolysis to prevent effector dysfunction, highlighting a role for controlled glutamine utilisation in maintaining T-cell fitness during chronic activation.

Glutamine Metabolism in Tumor Immunology publication trend

The graph below shows the total number of articles in glutamine metabolism in tumor immunology across all publications each year (not limited to Nature Index journals).

Technical terms

Glutaminolysis: Metabolic pathway converting glutamine into glutamate and downstream intermediates for energy and biosynthesis.

Conventional type-1 dendritic cell (cDC1): Subset of antigen-presenting cells specialised in priming CD8+ T-cell responses.

SLC38A2: Membrane transporter responsible for glutamine uptake in immune and tumour cells.

mTOR complex 1 (mTORC1): Protein kinase complex that integrates nutrient signals to regulate cell growth and metabolism.

Checkpoint blockade: Immunotherapy that inhibits regulatory receptors on T cells to enhance antitumour activity.

Tumour microenvironment (TME): Network of cancer cells, stromal cells and immune cells interacting through metabolic and signalling pathways.

References

1. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature (2023).
2. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nature Cancer (2023).
3. The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation. Nature Communications (2018).
4. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metabolism (2022).
5. Targeting glutamine metabolism as a therapeutic strategy for cancer. Experimental & Molecular Medicine (2023).
6. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Communication and Signaling (2022).